KR102849520B1 - 트레프로스티닐 프로드러그로 질환을 치료하는 방법 - Google Patents

트레프로스티닐 프로드러그로 질환을 치료하는 방법

Info

Publication number
KR102849520B1
KR102849520B1 KR1020237023390A KR20237023390A KR102849520B1 KR 102849520 B1 KR102849520 B1 KR 102849520B1 KR 1020237023390 A KR1020237023390 A KR 1020237023390A KR 20237023390 A KR20237023390 A KR 20237023390A KR 102849520 B1 KR102849520 B1 KR 102849520B1
Authority
KR
South Korea
Prior art keywords
substituted
prodrug
treprostinil
group
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237023390A
Other languages
English (en)
Korean (ko)
Other versions
KR20230134480A (ko
Inventor
케네스 로버트 파레스
히테쉬 바트라
리앙 궈
Original Assignee
유나이티드 쎄러퓨틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유나이티드 쎄러퓨틱스 코포레이션 filed Critical 유나이티드 쎄러퓨틱스 코포레이션
Priority to KR1020257027604A priority Critical patent/KR20250133451A/ko
Publication of KR20230134480A publication Critical patent/KR20230134480A/ko
Application granted granted Critical
Publication of KR102849520B1 publication Critical patent/KR102849520B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237023390A 2020-12-14 2021-12-13 트레프로스티닐 프로드러그로 질환을 치료하는 방법 Active KR102849520B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257027604A KR20250133451A (ko) 2020-12-14 2021-12-13 트레프로스티닐 프로드러그로 질환을 치료하는 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125145P 2020-12-14 2020-12-14
US63/125,145 2020-12-14
PCT/US2021/063133 WO2022132655A1 (en) 2020-12-14 2021-12-13 Methods of treating disease with treprostinil prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257027604A Division KR20250133451A (ko) 2020-12-14 2021-12-13 트레프로스티닐 프로드러그로 질환을 치료하는 방법

Publications (2)

Publication Number Publication Date
KR20230134480A KR20230134480A (ko) 2023-09-21
KR102849520B1 true KR102849520B1 (ko) 2025-08-25

Family

ID=79425461

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237023390A Active KR102849520B1 (ko) 2020-12-14 2021-12-13 트레프로스티닐 프로드러그로 질환을 치료하는 방법
KR1020257027604A Pending KR20250133451A (ko) 2020-12-14 2021-12-13 트레프로스티닐 프로드러그로 질환을 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257027604A Pending KR20250133451A (ko) 2020-12-14 2021-12-13 트레프로스티닐 프로드러그로 질환을 치료하는 방법

Country Status (9)

Country Link
US (3) US11826328B2 (enExample)
EP (1) EP4259121A1 (enExample)
JP (2) JP7826317B2 (enExample)
KR (2) KR102849520B1 (enExample)
CN (1) CN117062605A (enExample)
AU (1) AU2021401921A1 (enExample)
CA (1) CA3202061A1 (enExample)
IL (1) IL303668A (enExample)
WO (1) WO2022132655A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102849520B1 (ko) * 2020-12-14 2025-08-25 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
CN121241041A (zh) 2023-01-19 2025-12-30 联合治疗公司 曲前列尼尔类似物及相关制备和使用方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2485614A (en) 1946-08-29 1949-10-25 Chicago Bridge & Iron Co Stabilizing and guide apparatus for lifter roofs
US3037116A (en) 1957-07-26 1962-05-29 Weber Georges Apparatus for irradiating liquids
US3035516A (en) 1958-08-18 1962-05-22 Lee Brothers Company Stencil device
US3646509A (en) 1969-08-08 1972-02-29 Texas Instruments Inc Method for field stacking seismic data and system using write after read bulk data storage
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
US4547016A (en) 1984-08-13 1985-10-15 Eeco Incorporated Quick release mounting
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
IT1231076B (it) 1989-09-28 1991-11-12 Pirelli Cavi Spa Procedimento per la realizzazione di gruppo di connessione separabile per fibre ottiche riunite a nastro e gruppo di connessione con esso realizzato.
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
ES2214753T3 (es) 1997-11-14 2004-09-16 United Therapeutics Corporation Uso de 9-desoxi-2',9-alfa-metano-3-oxa-4,5,6-trinor-3,7-(1',3'-interfenilen)-13,14-dihidro-prostaglandina f1 para tratar la enfermedad vascular periferica.
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
KR20020012169A (ko) 1999-03-31 2002-02-15 유나이티드 쎄러퓨틱스 코포레이션 프로스타글란딘 화합물, 조성물 및 말초혈관질병 및폐고혈압증의 치료방법
US6700025B2 (en) 2001-01-05 2004-03-02 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US6756117B1 (en) 2002-12-20 2004-06-29 The United States Of America As Represented By The United States Department Of Energy Photonic polymer-blend structures and method for making
CN102697790A (zh) 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
CN1917866B (zh) 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
US7199157B2 (en) 2003-12-16 2007-04-03 United Therapeutics Corporation Use of treprostinil to improve kidney functions
DE602005020269D1 (de) 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
US8747897B2 (en) 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
CA2654492C (en) 2006-05-15 2017-06-27 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
CA2678258A1 (en) 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
CN103181893A (zh) 2007-09-07 2013-07-03 联合治疗公司 针对革兰氏阴性细菌具有选择性杀菌活性的缓冲液及其使用方法
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
JP6219016B2 (ja) 2008-05-08 2017-10-25 ユナイテッド セラピューティクス コーポレーション トレプロスチニル一水和物
CN102421288B (zh) 2009-05-07 2015-04-22 联合治疗公司 前列环素类似物的固体剂型
AU2010280684B2 (en) 2009-08-07 2016-07-28 Scipharm Sarl Composition for the treatment of cystic fibrosis
KR20160132501A (ko) 2010-03-15 2016-11-18 유나이티드 세러퓨틱스 코오포레이션 폐고혈압의 치료
CN103261142B (zh) 2010-06-03 2014-12-10 联合治疗公司 曲前列环素的制备
US20120010159A1 (en) * 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
CA2710725C (en) 2010-07-22 2017-08-01 Alphora Research Inc. Protected aldehydes for use as intermediates in chemical syntheses, and processes for their preparation
CA2710726C (en) 2010-07-22 2016-02-23 Alphora Research Inc. Synthesis of treprostinil and intermediates useful therein
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
ES2581762T3 (es) 2011-03-02 2016-09-07 United Therapeutics Corporation Síntesis de producto intermedio para la producción de treprostinil
US9388154B2 (en) 2011-09-12 2016-07-12 Lund Biotechnology PBC Process for preparing synthetic prostacyclins
CN103193626B (zh) 2012-01-10 2016-05-11 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
CN103193627B (zh) 2012-01-10 2016-04-20 上海天伟生物制药有限公司 一种前列腺素类似物的晶型及其制备方法和用途
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
SI2674413T1 (sl) 2012-06-15 2017-10-30 Scipharm Sarl Postopek za pripravo treprostinila in derivatov le-tega
WO2014085813A1 (en) 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
CN104837806A (zh) 2012-12-07 2015-08-12 开曼化学股份有限公司 前列环素类似物的合成方法
US9505737B2 (en) * 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
EP2970081A4 (en) 2013-03-15 2016-10-12 United Therapeutics Corp SALTS OF TREPROSTINIL
CA2911172C (en) 2013-04-30 2021-10-19 United Therapeutics Corporation Controlled release pharmaceutical formulations
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
WO2015174197A1 (ja) 2014-05-14 2015-11-19 富士電機株式会社 半導体装置および半導体装置の製造方法
ES2908142T3 (es) 2014-06-13 2022-04-27 United Therapeutics Corp Formulaciones de treprostinil
US20160045470A1 (en) 2014-08-12 2016-02-18 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of treprostinil diethanolamine
WO2016038532A1 (en) 2014-09-09 2016-03-17 Mylan Laboratories Limited Amorphous treprostinil diethanolamine
HU231184B1 (hu) 2014-10-08 2021-07-28 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Treprostinil-nátrium-monohidrát és eljárás ennek előállítására
CN107108427A (zh) 2014-10-20 2017-08-29 联合治疗学有限公司 用于制备前列环素衍生物的中间体的合成
US10343979B2 (en) * 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (zh) 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 曲前列環素二乙醇胺之合成方法及新穎中間體
WO2016105538A1 (en) 2014-12-23 2016-06-30 Sandia Corporation Sandia National Laboratories Adjusting the ph of a pretreatment solution using carbon dioxide useful for integrating saccharification and fermentation
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2018058124A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
CN114616225A (zh) * 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
KR102849520B1 (ko) * 2020-12-14 2025-08-25 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법

Also Published As

Publication number Publication date
IL303668A (en) 2023-08-01
EP4259121A1 (en) 2023-10-18
US20240130989A1 (en) 2024-04-25
KR20230134480A (ko) 2023-09-21
JP2023553989A (ja) 2023-12-26
US20260069557A1 (en) 2026-03-12
CN117062605A (zh) 2023-11-14
WO2022132655A1 (en) 2022-06-23
JP2026102630A (ja) 2026-06-23
US12491170B2 (en) 2025-12-09
JP7826317B2 (ja) 2026-03-09
AU2021401921A1 (en) 2023-07-06
KR20250133451A (ko) 2025-09-05
US20220323387A1 (en) 2022-10-13
US11826328B2 (en) 2023-11-28
CA3202061A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
EP4017588A1 (en) Treprostinil prodrugs
US20260069557A1 (en) Stable treprostinil prodrugs
RU2523543C2 (ru) Соли производных тетерагидро-имидазо[1,5-a]пиразина, способы их получения и их медицинское применение
JP2002517459A (ja) β２−アドレナリン作動性レセプターアゴニスト
IT8149031A1 (it) Amidi organiche derivate da lipidi azotati utilizzabili come farmaci
KR20240012354A (ko) (e)-3,6-비스[4-(n-카보닐-2-프로페닐)아미도부틸]-2,5-디케토피페라진(fdkp)을 추가로 포함하는, 트레프로스티닐 및 이의 프로드러그의 건조 분말 조성물
WO1990007330A1 (en) Selection method for specific useful pharmaceutical compounds
AU2014292722A1 (en) Quinine compounds, and optical isomers, preparation method and medical use thereof
JPH03181483A (ja) フイソスチグミンに関連したアミノカルボニルカルバメート
AU2024289343A1 (en) Treprostinil derivative, and preparation method therefor and use thereof
JPH0335319B2 (enExample)
US20240262783A1 (en) Pharmaceutical salt of fingolimod, preparation method, pharmaceutical composition and use thereof
HK40114273A (en) Treprostinil derivative, and preparation method and use thereof
WO2024131672A1 (zh) 二苯基吡嗪类衍生物、其制备方法及应用
CN120058616A (zh) 2-取代-1h-苯并咪唑类化合物及其制备方法和用途
CN118891248A (zh) 苯乙胺及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D16-exm-PA0302

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000